Literature DB >> 8227731

Post-operative acute respiratory failure associated with Mycobacterium xenopi.

J M Rousseau, L Brinquin, Y Diraison, J P Bonsignour.   

Abstract

Entities:  

Mesh:

Year:  1993        PMID: 8227731     DOI: 10.1007/bf01694715

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  9 in total

1.  Anonymous mycobacteria in pulmonary disease.

Authors:  E H RUNYON
Journal:  Med Clin North Am       Date:  1959-01       Impact factor: 5.456

2.  Diagnosis and treatment of disease caused by nontuberculous mycobacteria.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1990-10

3.  Pulmonary infection with nontuberculous mycobacteria.

Authors:  M A Contreras; O T Cheung; D E Sanders; R S Goldstein
Journal:  Am Rev Respir Dis       Date:  1988-01

4.  An expanded definition of the adult respiratory distress syndrome.

Authors:  J F Murray; M A Matthay; J M Luce; M R Flick
Journal:  Am Rev Respir Dis       Date:  1988-09

5.  Disseminated Mycobacterium xenopi infection.

Authors:  J R Weinberg; G Dootson; D Gertner; S T Chambers; H Smith
Journal:  Lancet       Date:  1985-05-04       Impact factor: 79.321

6.  Adult respiratory distress syndrome secondary to activated miliary tuberculosis following surgery.

Authors:  S S Fieber; J D Cohn; F M Jacobs
Journal:  J Med Soc N J       Date:  1979-05

7.  Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi.

Authors:  A M Costrini; D A Mahler; W M Gross; J E Hawkins; R Yesner; N D D'Esopo
Journal:  Am Rev Respir Dis       Date:  1981-01

8.  Pulmonary infection with mycobacterium xenopi: review of treatment and response.

Authors:  J Banks; A M Hunter; I A Campbell; P A Jenkins; A P Smith
Journal:  Thorax       Date:  1984-05       Impact factor: 9.139

9.  The adult respiratory distress syndrome bronchogenic pulmonary tuberculosis.

Authors:  R A Dyer; P D Potgieter
Journal:  Thorax       Date:  1984-05       Impact factor: 9.139

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.